GSK will fight NICE provisional rejection of Benlysta for SLE
This article was originally published in Scrip
Executive Summary
In draft guidance, NICE, the health technology appraisal institute for England and Wales, has provisionally rejected GlaxoSmithKline and Human Genome Sciences' (HGS), belimumab (Benlysta), for the treatment of adult patients with active autoantibody-positive systemic lupus erythematosus, where patients have a high degree of disease activity despite the individual receiving standard therapy.